There's nothing like free publicity to help goose the sales of a relatively new product. Cancer-diagnostics specialist Guardant Health (GH 5.87%) was a standout in the biotech sector on Hump Day. Investors cheered the company's news that one of its products made it onto a list of top innovations compiled by a familiar magazine. In response, they traded Guardant's shares up by almost 6%, making it quite the outperformer when matched against the S&P 500 index's 0.3% drop on the day. One of the top innovations ...

Guardant Health (GH) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on Nove ...

Guardant Health needs cash. Until it can get it from selling enough services, it must sell its own shares instead. Shares of precision medicine company Guardant Health (GH -11.13%), which specializes in liquid biopsies to test for cancer, fell 10.6% through 10:05 a.m. ET Monday morning. Monday was the first trading day in which investors got to react to a Guardant announcement late Friday, that it plans to sell stock and raise $400 million in new cash to fund its operations. Guardant needs money Guardant's ...

After reaching an important support level, Guardant Health (GH) could be a good stock pick from a technical perspective. GH surpassed resistance at the 20-day moving average, suggesting a short-term bullish trend. The 20-day simple moving average is a popular trading tool. It provides a look back at a stock's price over a 20-day period, and is beneficial to short-term traders since it smooths out price fluctuations and provides more trend reversal signals than longer-term moving averages. The 20-day moving ...

Wall Street analysts forecast that Guardant Health (GH) will report quarterly loss of $0.57 per share in its upcoming release, pointing to a year-over-year increase of 14.9%. It is anticipated that revenues will amount to $161.93 million, exhibiting an increase of 18.1% compared to the year-ago quarter. The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial p ...

signal a downward trend. After reaching an important support level, Guardant Health (GH) could be a good stock pick from a technical perspective. GH surpassed resistance at the 20-day moving average, suggesting a short-term bullish trend. The 20-day simple moving average is a popular trading tool. It provides a look back at a stock's price over a 20-day period, and is beneficial to short-term traders since it smooths out price fluctuations and provides more trend reversal signals than longer-term moving ave ...

After reaching an important support level, Guardant Health, Inc. (GH) could be a good stock pick from a technical perspective. GH recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average. A golden cross is a technical chart pattern that can signify a potential bullish breakout. It's formed from a crossover involving a security's short-term moving average breaking above a longer-term moving average, with the most common movin ...

Group 1 - Guardant Health (GH) has recently reached a key level of support and has overtaken the 200-day moving average, indicating a long-term bullish trend [1] - GH has moved 47.1% higher over the last four weeks, suggesting potential for another rally [2] - The company has a Zacks Rank 3 (Hold) and has seen positive earnings estimate revisions, with 5 higher estimates compared to none lower for the current fiscal year [2] Group 2 - Investors are encouraged to consider adding GH to their watchlist due to the important technical indicator and positive earnings estimate revisions [3]

Guardant Health (GH) stock rocketed Friday after a Food and Drug Administration panel recommended the agency approve Guardant's blood-based colon cancer screening test. X The FDA's Medical Devices Advisory Committee voted eight to one that Guardant's blood-based test, known as Shield, is safe. Six out of nine panelists said the test appears effective, and seven to two voted that the benefits outweigh the risks. If approved, Guardant's blood-based test would rival Exact Sciences' (EXAS) Cologuard, an already ...

For the quarter ended March 2024, Guardant Health (GH) reported revenue of $168.49 million, up 30.9% over the same period last year. EPS came in at -$0.46, compared to -$1.30 in the year-ago quarter.The reported revenue represents a surprise of +11.94% over the Zacks Consensus Estimate of $150.51 million. With the consensus EPS estimate being -$0.72, the EPS surprise was +36.11%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall S ...